Pharma & Biotech - Page 3

Australian plasma and vaccine specialist CSL posted signs of a meaningful recovery on Tuesday after a turbulent year marked by impairments, revenue downgrades, and an executive shakeup. The company’s fiscal 2026 report

Revance, a global aesthetics and skincare company, has named Janelle Wichmann as its new Chief Marketing Officer for its skincare division. Wichmann will report directly to Nadeem Moiz, who serves as Chief

IAG Cargo has added Kuala Lumpur as an approved Constant Climate station, strengthening its pharmaceutical logistics presence across Southeast Asia. The move brings the total number of approved Constant Climate locations in

Eurofins Scientific (EUFI) is expanding its high-potency active pharmaceutical ingredient manufacturing operations through its Eurofins CDMO Alphora unit based in Mississauga, Canada. The expansion targets both standard and high-potency small molecule development

Sandoz has struck a major deal with China’s Shanghai Henlius Biotechnology, securing commercialisation rights to three biosimilars currently in early development. The Swiss pharmaceutical company will pay up to $100.5 million upfront

AstraZeneca has reported positive phase 3 results from two separate non-small cell lung cancer trials, though the wins have done little to offset a significant setback elsewhere in its pipeline. The British

Sanofi is laying off 229 employees from its acquired Blueprint Medicines business in Massachusetts as part of a post-acquisition integration process. The cuts were detailed in a state Worker Adjustment and Retraining

EyePoint Pharmaceuticals (EYPT) saw its stock collapse by more than 70% on Monday after its drug-device combination Duravyu stumbled in its first of two phase 3 trial readouts this year. The company

Quanovate Tech, Inc. has voluntarily discontinued a series of advertising claims for its Mira Fertility Monitor and Test Wands following a challenge by The Procter & Gamble Company. The challenge was brought

The debate around separating the measles, mumps and rubella vaccine has focused heavily on public health, parental choice, and vaccine policy choices. However, the pharmaceutical industry faces a distinct and urgent question